Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Place any order that is greater than $500 and get a mystery box from ACROBiosystems!
Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μl stock solution per million cells (QC tested).
FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti- human PD-L1 antibody. The IC50 is 0.29 μg/ml (QC tested).
Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Prolgolimab | BCD-100 | Approved | Biocad | Forteca | Russian Federation | Melanoma | s:6:"Biocad"; | 2020-04-01 | Carcinoma, Non-Small-Cell Lung; Melanoma; Uterine Cervical Neoplasms | Details |
Camrelizumab | SHR-1210; INCSHR-1210; HR-301210 | Approved | Suzhou Suncadia Biopharmaceuticals Co Ltd, Jiangsu Hengrui Medicine Co Ltd | 艾立妥, 艾瑞卡 | Mainland China | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung | s:41:"Suzhou Suncadia Biopharmaceuticals Co Ltd"; | 2019-05-29 | Lymphoma, Extranodal NK-T-Cell; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Squamous Cell; Endometrial Neoplasms; Lung Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Respiratory Tract Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Breast Neoplasms; Lung Diseases; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Carcinoma, Renal Cell; Bronchial Neoplasms; Thoracic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Solid tumours; Carcinoma, Bronchogenic | Details |
Tislelizumab | BGB-A317 | Approved | Beigene Ltd | 百泽安 | Mainland China | Carcinoma, Transitional Cell | s:11:"Beigene Ltd"; | 2019-12-26 | Breast Neoplasms; Melanoma; Leukemia, Lymphocytic, Chronic, B-Cell; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma, Large-Cell, Anaplastic; Carcinoma, Squamous Cell; Lymphoma, T-Cell; Esophageal Squamous Cell Carcinoma; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Microsatellite Instability; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Hodgkin Disease; Stomach Neoplasms; Esophageal Neoplasms; Lymphoma, T-Cell, Peripheral; Solid tumours | Details |
Toripalimab | JS-001; SO-001; TAB-001 | Approved | Shanghai Junshi Biosciences Co Ltd, Suzhou Union Biopharm Biosciences Co Ltd | 拓益 | Mainland China | Melanoma | s:34:"Shanghai Junshi Biosciences Co Ltd"; | 2018-12-17 | Solid tumours; Kidney Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Nivolumab | MDX-1106; ONO-4538; ono-0123; BMS-936558; BMS-936558-01 | Approved | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | 欧狄沃, Opdivo | EU | Esophageal Squamous Cell Carcinoma | s:32:"Bristol-Myers Squibb Pharma Eeig"; | 2014-07-04 | Esophageal Squamous Cell Carcinoma; Mesothelioma; Multiple Myeloma; Breast Neoplasms; Microsatellite Instability; Sarcoma; Cholangiocarcinoma; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Diarrhea; Colorectal Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Hepatitis C; Prostatic Neoplasms, Castration-Resistant; Glioma; Lymphoma; Carcinoma, Squamous Cell; Lung Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Uterine Cervical Neoplasms; Irritable Bowel Syndrome; Head and Neck Neoplasms; Ovarian Neoplasms; Bone Marrow Neoplasms; Solid tumours; Chondrosarcoma; Lymphoma, B-Cell; Kidney Neoplasms; Liver Neoplasms; Carcinoma, Merkel Cell; Carcinoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Hematologic Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional | Details |
Sintilimab | IBI-308 | Approved | Innovent Biologics(Suzhou) Co Ltd | 达伯舒, Tyvyt | Mainland China | Hodgkin Disease | s:33:"Innovent Biologics(Suzhou) Co Ltd"; | 2018-12-24 | Solid tumours; Esophageal Neoplasms; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Colorectal Neoplasms; Lung Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Uterine Cervical Neoplasms | Details |
Cemiplimab | REGN-2810; SAR-439684 | Approved | Regeneron Pharmaceuticals Inc | Libtayo | EU | Carcinoma, Squamous Cell | s:20:"Regeneron Ireland Uc"; | 2018-09-28 | Peritoneal Neoplasms; Uterine Cervical Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Fallopian Tube Neoplasms; Glioma; Lymphoma; Endometrial Neoplasms; Carcinoma, Squamous Cell; Ovarian Neoplasms; Diffuse Intrinsic Pontine Glioma; Hepatitis B; Prostatic Neoplasms; Hodgkin Disease; Glioblastoma; Carcinoma, Renal Cell; Carcinoma, Basal Cell; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
Pembrolizumab | h409A11; MK-3475; SCH-900475 | Approved | Merck & Co Inc | 可瑞达, Keytruda | United States | Triple Negative Breast Neoplasms | s:14:"Merck & Co Inc"; | 2014-09-04 | Urinary Bladder Diseases; Breast Diseases; Neoplasms, Nerve Tissue; Gliosarcoma; Urologic Neoplasms; Bile Duct Neoplasms; Parotid Neoplasms; Thymus Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Neurofibrosarcoma; Respiratory Tract Neoplasms; Sarcoma; Esophageal adenocarcinoma; Vulvar Neoplasms; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Microsatellite Instability; Brain Neoplasms; Lymphoma, Follicular; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Multiple Myeloma; Thyroid Neoplasms; Carcinoma, Endometrioid; Gastrointestinal Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Leukemia, Myeloid, Acute; Esophageal Squamous Cell Carcinoma; Liposarcoma; Epstein-Barr Virus Infections; Carcinoma, Small Cell; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Lymphoma, Non-Hodgkin; Carcin | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Hodgkin Disease; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | Details | |
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
PD-1 knockout engineered T cells (Chengdu MedGenCell) | Phase 2 Clinical | West China Hospital Of Sichuan University, Chengdu Medgencell | Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details | |
RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Solid tumours; Lymphoma | Details |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
HX-009 | HX-009 | Phase 1 Clinical | Hangzhou Hansi Biomedicine Co Ltd, Wuhan Hanxiong Biotechnology Co Ltd | Liver Neoplasms; Hematologic Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Recombinant human anti-PD-1 monoclonal antibody(Sumgen) | SG-001 | Phase 1 Clinical | Hangzhou Sumgen Biotechnology Co Ltd | Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics | Ovarian Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Lymphoma, Large B-Cell, Diffuse; Breast Neoplasms; Carcinoma, Hepatocellular | Details |
MAX-10181 | MAX-1; MAX-10181 | Phase 1 Clinical | Guangzhou Maxinovel Pharmaceiticals Co Ltd | Neoplasms | Details |
CX-188 | Phase 1 Clinical | Cytomx Therapeutics | Neoplasms | Details | |
XmAb-23104 (Xencor) | Phase 1 Clinical | Xencor | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details | |
Nivolumab/Relatlimab | BMS-986213; BMS-936558/BMS-986016 | Phase 3 Clinical | Bristol-Myers Squibb Company | Stomach Neoplasms; Melanoma | Details |
Sym-021 | Sym-021 | Phase 1 Clinical | Symphogen | Lymphoma; Neoplasm Metastasis | Details |
MGD-019 (MacroGenics) | MGD-019 | Phase 1 Clinical | Macrogenics | Colorectal Neoplasms | Details |
Budigalimab | ABBV-181 | Phase 1 Clinical | Abbvie Inc | Ovarian Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 2 Clinical | Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital | Esophageal Neoplasms | Details | |
W0180 | Phase 1 Clinical | Pierre Fabre Medicament | Neoplasms | Details | |
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera) | BAT-1306 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Liver Neoplasms; Stomach Neoplasms; Colorectal Neoplasms | Details |
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 1 Clinical | Anhui Anke Biotechnology (Group)Co Ltd | Esophageal Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Lymphoma; Lung Neoplasms | Details | |
RO-7247669 | RO-7247669 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
LZM-009 | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Thymoma; Carcinoma, Non-Small-Cell Lung | Details |
Programmed cell death 1 antibody (Sun Yat-sen University) | Phase 2 Clinical | Sun Yat-Sen University | Carcinoma, Hepatocellular | Details | |
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian) | Phase 1 Clinical | Shanghai Cp Guojian Pharmaceutical Co Ltd | Solid tumours | Details | |
PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Stomach Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Lymphoma | Details | |
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing) | Phase 2 Clinical | Chongqing Xinqiao Hospital | Squamous Cell Carcinoma of Head and Neck | Details | |
IBI315 | IBI315; IBI-315 | Phase 1 Clinical | Innovent Biologics(Suzhou) Co Ltd, Hanmi Pharmaceutical Co Ltd | Neoplasms | Details |
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | Details | |
ONO-4685 | ONO-4685 | Phase 1 Clinical | Merus | Autoimmune Diseases | Details |
T3011疱疹病毒(深圳市亦诺微医药) | Phase 1 Clinical | Shenzhen Yinuowei Pharmaceutical Technology Co Ltd | Head and Neck Neoplasms; Esophageal Neoplasms; Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis | Details | |
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical) | Phase 2 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, T-Cell, Peripheral; Carcinoma, Transitional Cell; Neurolymphomatosis; Lymphoma; Uterine Cervical Neoplasms | Details | |
MEDI-5752 | MEDI-5752 | Phase 1 Clinical | Medimmune Llc | Carcinoma, Renal Cell; Neoplasms | Details |
YBL-006 | YBL-006; YBL 006 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | Details | |
Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Yangshengtang Co Ltd, Xiamen University | Liver Neoplasms; Head and Neck Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Melanoma | Details | |
BCD-217 | BCD-217 | Phase 2 Clinical | Biocad | Melanoma | Details |
PD-1 knockout engineered T cells (Cell Biotech) | Phase 1 Clinical | Cell Biotech | Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Prostatic Neoplasms | Details | |
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech) | SCT-I10A | Phase 3 Clinical | Shenzhou Cell Engineering Co Ltd | Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Lymphoma; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular | Details |
IMU-201 | IMU-201 | Phase 1 Clinical | Imugene | Carcinoma, Non-Small-Cell Lung | Details |
609-A (SBio) | 609-A | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Neoplasms | Details |
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxiweiqidaguangming Pharmaceutical Co Ltd | Solid tumours | Details | |
XmAb20717 | XmAb-20717 | Phase 1 Clinical | Xencor | Astrocytoma; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Endometrial Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Neuroendocrine; Thymoma; Colorectal Neoplasms; Carcinoma, Renal Cell; Prostatic Neoplasms; Vulvar Neoplasms; Breast Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Mesothelioma; Carcinoma, Ovarian Epithelial; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Basal Cell | Details |
MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin | Details | |
TY-101 | TY-101; TY101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Solid tumours; Neoplasms; Lymphoma | Details |
RO-7121661 | RG-7769; RO-7121661 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Small Cell Lung Carcinoma; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
AK-112 | AK-112 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Mali Biotechnology Co Ltd, Chengdu Yinhe Biomedicine Co Ltd | Lymphoma, B-Cell | Details | |
IBI318 | IBI-318; LY-3434172; LY3434172 | Phase 2 Clinical | Eli Lilly And Company, Innovent Biologics(Suzhou) Co Ltd | Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular | Details |
Sasanlimab | RN-888; PF-6801591; PF-06801591 | Phase 3 Clinical | Pfizer Pharmaceuticals Ltd (China) | Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Endometrial Neoplasms; Bile Duct Neoplasms; Sarcoma; Prostatic Neoplasms; Urinary Bladder Neoplasms; Ovarian Neoplasms; Carcinoma, Transitional Cell; Carcinoma, Renal Cell; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Solid tumours | Details |
Recombinant humanized anti-PD-1 monoclonal antibody(Akeso Biopharma) | AK-103; HX-008 | Phase 3 Clinical | Zhongshan Akeso Biopharma Co Ltd, Taizhou Hanzhong Biomedical Co Ltd, Hangzhou Hansi Biomedicine Co Ltd | Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Thyroid Carcinoma, Anaplastic; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Melanoma; Adenocarcinoma; Gastrointestinal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
ONCR-177 | ONCR-177 | Phase 1 Clinical | Oncorus | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Breast Neoplasms; Melanoma | Details |
CMAB-819 | CMAB8-19 | Phase 1 Clinical | Sinomab Bioscience Ltd | Squamous Cell Carcinoma of Head and Neck; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Renal Cell; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
JTX-4014 (Jounce Therapeutics) | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics | Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Spartalizumab | PDR-001 | Phase 3 Clinical | Novartis Pharma Ag | Sarcoma, Alveolar Soft Part; Neuroendocrine Tumors; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Breast Neoplasms; Sarcoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Primary Myelofibrosis; Bone Marrow Diseases; Carcinoma, Pancreatic Ductal; Esophageal Squamous Cell Carcinoma; Chordoma; Endometrial Neoplasms; Lung Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute; Esophageal adenocarcinoma; Carcinoma, Hepatocellular; Melanoma; Carcinoma, Non-Small-Cell Lung; Persistent Fetal Circulation Syndrome; Stomach Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Leukemia; Leukemia, Myeloid; Head and Neck Neoplasms; Kidney Neoplasms; Preleukemia; Hematologic Diseases; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Thyroid Carcinoma, Anaplastic; Pancreatic Neoplasms; Neoplasms, Squamous Cell; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Digestive System Neoplasms; Multi | Details |
CA-170 | CA-170; AUPM-170 | Phase 2 Clinical | Aurigene | Solid tumours; Neoplasms | Details |
CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio | Autoimmune Diseases; Psoriasis | Details |
INCB-086550 | INCB-086550 | Phase 2 Clinical | Incyte Corp | Solid tumours; Carcinoma; Carcinoma, Renal Cell; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
Balstilimab | AGEN2034; RebmAb-700 | Phase 2 Clinical | Ludwig Institute For Cancer Research, Agenus Inc | Hemangiosarcoma; Uterine Cervical Neoplasms | Details |
AK-104 | AK-104 | Phase 2 Clinical | Zhongshan Akeso Biopharma Co Ltd | Lymphoma, T-Cell, Peripheral; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Nasopharyngeal Carcinoma; Microsatellite Instability; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Melanoma | Details |
Retifanlimab | INCMGA-0012; INCMGA-00012; MGA-012 | Phase 3 Clinical | Macrogenics | Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis; Melanoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Solid tumours; Esophageal Neoplasms; Carcinoma, Merkel Cell; Stomach Neoplasms; Carcinoma, Renal Cell; Anus Neoplasms; Head and Neck Neoplasms; Ovarian Neoplasms | Details |
AMG-404 | AMG-404 | Phase 1 Clinical | Amgen Inc | Solid tumours; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms | Details |
CS-1003 | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Solid tumours; Neoplasms; Lymphoma; Carcinoma, Hepatocellular | Details |
MEDI-0680 | AMP-514; MEDI-0680 | Phase 2 Clinical | Medimmune | Kidney Neoplasms; Lymphoma, B-Cell; Carcinoma, Renal Cell | Details |
BI-754091 | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Solid tumours; Head and Neck Neoplasms; Rectal Neoplasms; Neoplasms; Colonic Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
Cetrelimab | JNJ-3283; JNJ-63723283 | Phase 3 Clinical | Johnson & Johnson | Carcinoma, Transitional Cell; Multiple Myeloma; Urinary Bladder Neoplasms | Details |
HLX-10 | HLX-10 | Phase 3 Clinical | Shanghai Henlius Biotech Co Ltd | Solid tumours; Head and Neck Neoplasms; Liver Neoplasms; Hepatitis B, Chronic; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Esophageal Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Microsatellite Instability; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Carcinoma, Hepatocellular; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
STW204单抗 | STW-204 | Phase 1 Clinical | Suzhou Sitanwei Biological Technology Co Ltd | Solid tumours | Details |
Pidilizumab | CT-011; MDV-9300 | Phase 2 Clinical | Curetech | Carcinoma, Renal Cell; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Multiple Myeloma; Lymphoma, Follicular; Prostatic Neoplasms; Hepatitis C; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Glioma; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Carcinoma, Hepatocellular; Hepatitis C, Chronic | Details |
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology) | Phase 1 Clinical | Hengrui Yuanzheng Biotechnology Co Ltd | Solid tumours; Stomach Neoplasms | Details | |
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology) | Phase 1 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Neoplasms | Details |
This web search service is supported by Google Inc.